Psoriasis Biologics: IL-17 vs IL-23 Inhibitors in Head-to-Head Trials
IL-17 Inhibitors: Secukinumab, Ixekizumab, Brodalumab, Bimekizumab
IL-17A inhibitors (secukinumab 300 mg, ixekizumab 80 mg) and the IL-17 receptor antagonist brodalumab 210 mg provide rapid and robust skin clearance. In the FIXTURE trial, secukinumab achieved PASI 90 in 59% at week 16. Ixekizumab demonstrated PASI 90 of 71% at week 12 in UNCOVER-3. Bimekizumab, a dual IL-17A/IL-17F inhibitor, achieved PASI 100 of 59% at week 16 in the BE READY trial, the highest complete clearance rate reported for any biologic. Oral candidiasis is the class-specific adverse event, occurring in 2-16% of patients (highest with bimekizumab at 16%).
IL-23 Inhibitors: Guselkumab, Risankizumab, Tildrakizumab
IL-23p19 inhibitors target the upstream cytokine driving Th17 cell differentiation. Guselkumab (100 mg q8w after loading) achieved PASI 90 of 73% at week 48 in VOYAGE-1. Risankizumab (150 mg q12w after loading) achieved PASI 90 of 75% at week 16 in UltIMMa-1 and UltIMMa-2. Tildrakizumab (100 mg q12w) offers a more modest efficacy profile (PASI 90 of 35% at week 28 in reSURFACE-2) but maintains a favorable safety record with the lowest injection frequency in the class. The IL-23 class is notable for exceptional durability, with rising PASI 90 rates through week 52 and beyond.
Head-to-Head Trials: The Key Comparisons
The IMMerge trial compared risankizumab versus secukinumab, showing risankizumab superiority at week 52 (PASI 90: 87% vs 57%, p<0.001). The ECLIPSE trial demonstrated guselkumab superiority over secukinumab at week 48 (PASI 90: 84% vs 70%, p<0.001). Bimekizumab showed superiority over secukinumab at week 16 (PASI 100: 61% vs 49%, p=0.011) in the BE RADIANT trial, though durability data favor IL-23 agents. The BE VIVID trial showed bimekizumab superiority over ustekinumab (PASI 90: 86% vs 47% at week 16).
Sponsored
Selecting Between IL-17 and IL-23: Clinical Framework
IL-17 inhibitors offer faster onset (measurable within 1-2 weeks), making them preferred when rapid clearance is clinically important. IL-23 inhibitors offer superior durability with less frequent dosing and rising efficacy over time, making them ideal for long-term maintenance. For patients with concomitant psoriatic arthritis, both classes are effective, but IL-17 inhibitors have more extensive joint data. IL-17 agents are contraindicated in active inflammatory bowel disease (risk of IBD flare), making IL-23 inhibitors the preferred choice in patients with comorbid Crohn disease or ulcerative colitis.
Safety and Monitoring Considerations
Both IL-17 and IL-23 inhibitor classes have favorable long-term safety profiles based on 5+ years of extension study data. Neither class requires routine laboratory monitoring. The main differentiators are candidiasis risk (higher with IL-17, especially bimekizumab) and the theoretical IBD risk with IL-17 agents. Infection rates are comparable to TNF inhibitors without the elevated tuberculosis reactivation risk. Pre-treatment screening should include hepatitis B/C serologies, tuberculosis testing, and assessment for IBD symptoms. Live vaccines should be avoided during active treatment with either class.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.